Results 251 to 260 of about 7,007,196 (291)
Some of the next articles are maybe not open access.
Journal of Substance Abuse Treatment, 2014
The New Jersey Medication Assisted Treatment Initiative (NJ-MATI) sought to reduce barriers to treatment by providing free, opioid agonist treatment (OAT, methadone or buprenorphine) via mobile medication units (MMUs). To evaluate barriers to OAT, logistic regression was used to compare opioid dependent patients enrolled in NJ-MATI to those entering ...
Gerod, Hall +9 more
openaire +2 more sources
The New Jersey Medication Assisted Treatment Initiative (NJ-MATI) sought to reduce barriers to treatment by providing free, opioid agonist treatment (OAT, methadone or buprenorphine) via mobile medication units (MMUs). To evaluate barriers to OAT, logistic regression was used to compare opioid dependent patients enrolled in NJ-MATI to those entering ...
Gerod, Hall +9 more
openaire +2 more sources
Pay for Performance and Treatment Outcome in Agonist Treatment for Opioid Use Disorder
The American Journal on Addictions, 2020Background and ObjectivesPay for performance (P4P) models have become more popular in reimbursement for medical services, including treatment for substance use disorders. However, studies have not examined whether P4P has an impact on treatment outcome in the individual in opioid agonist treatment (OAT).
Emily Loscalzo +3 more
openaire +2 more sources
Chronic Agonist Treatment Converts Antagonists into Inverse Agonists at δ-Opioid Receptors
The Journal of Pharmacology and Experimental Therapeutics, 2002In cellular models, chronic exposure to mu-opioid agonists converts antagonists into inverse agonists at mu-receptors. Such adaptations could contribute to the development of tolerance and/or dependence. To determine whether delta-receptors respond similarly, or whether this adaptation is unique for mu-receptors, this study examined the effects of ...
Jing-Gen, Liu, Paul L, Prather
openaire +2 more sources
Regulation of dynorphin gene expression by κ-opioid agonist treatment
Neuroreport, 2002The effects of K-opioid agonist treatment on prodynorphin mRNA expression in the rat brain were studied. Rats were treated with the selective kappa-opioid agonist U-69593 or vehicle for 5 days and prodynorphin mRNA was measured on day 8 (3 days after the last injection) or 22 (17 days after the last injection).
COLLINS S +4 more
openaire +3 more sources
Outcome evaluation of the opioid agonist maintenance treatment in
AbstractIntroduction and AimsMethadone maintenance treatment and buprenorphine maintenance treatment are the two main therapeutic options considered for opioid replacement therapy. This study was conducted to examine the effectiveness of methadone maintenance treatment and buprenorphine maintenance treatment in Iran under usual clinical conditions ...
Esmaeili, Hamid-Reza +4 more
openaire +4 more sources
Mixed Agonist/Antagonist Opioids in the Treatment of Pain
2022Mixed agonist/antagonist opioids have recently been gaining popularity among pain and palliative care providers due to their decreased likelihood of causing fatal adverse events, such as respiratory depression. However lack of comfort with dosing and administration severely reduces use.
openaire +1 more source
The urgent need for opioid agonist treatment in Russia
The Lancet HIV, 2023Leah, Harvey +2 more
openaire +2 more sources
A truly patient-centred evaluation of opioid agonist treatment
The Lancet Psychiatry, 2023Joan, Trujols +3 more
openaire +2 more sources
Opioid agonist treatment for self-harm and suicide prevention
The Lancet Psychiatry, 2022Paul S, Nestadt, Alison, Athey
openaire +2 more sources
Implementing Opioid Agonist Treatment in Correctional Facilities
JAMA Internal Medicine, 2018Kevin, Fiscella +2 more
openaire +2 more sources